Kymera Therapeutics price target raised to $60 from $52 at Citi

Citi raised the firm’s price target on Kymera Therapeutics (KYMR) to $60 from $52 and keeps a Buy rating on the shares. Positive Phase 1 healthy volunteer data for KT-621 de-risks the asset and underscores the potential of Kymera’s platform, the analyst tells investors. The firm believes this potent efficacy, clean safety, and promising biomarker data, though in healthy volunteers, “strongly derisks” KT-621 and Citi increased its view of the odds of success for KT-621 to 15% from 10% and now models peak 2030 sales of $520M, the analyst added.